Benzinga | Sep 13, 2021 04:51AM EDT

Raymond James Upgrades NGM Biopharmaceuticals to Strong Buy, Raises Price Target to $39

Raymond James analyst Steven Seedhouse upgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Outperform to Strong Buy and raises the price target from $27 to $39.